The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Longitudinal study of normal cognition in Parkinson disease
Open accessAbstract
OBJECTIVE: To report the rates and predictors of progression from normal cognition to either mild cognitive impairment (MCI) or dementia using standardized neuropsychological methods. METHODS: A prospective cohort of patients diagnosed with Parkinson disease (PD) and baseline normal cognition was assessed for cognitive decline, performance, and function for a minimum of 2 years, and up to 6. A panel of movement disorders experts classified patients as having normal cognition, MCI, or dementia, with 55/68 (80.9%) of eligible patients seen at year 6. Kaplan-Meier curves and Cox proportional hazard models were used to examine cognitive decline and its predictors. RESULTS: We enrolled 141 patients, who averaged 68.8 years of age, 63% men, who had PD on average for 5 years. The cumulative incidence of cognitive impairment was 8.5% at year 1, increasing to 47.4% by year 6. All incident MCI cases had progressed to dementia by year 5. In a multivariate analysis, predictors of future decline were male sex (p = 0.02), higher Unified Parkinson's Disease Rating Scale motor score (p ≤ 0.001), and worse global cognitive score (p < 0.001). CONCLUSIONS: Approximately half of patients with PD with normal cognition at baseline develop cognitive impairment within 6 years and all new MCI cases progress to dementia within 5 years. Our results show that the transition from normal cognition to cognitive impairment, including dementia, occurs frequently and quickly. Certain clinical and cognitive variables may be useful in predicting progression to cognitive impairment in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 6-year longitudinal study of 141 PD patient with average disease duration of 5 years and a mean age of 69 years showed a cumulative risk of dementia increasing from 8.5% at 1 year to nearly 50% by year 6 (Pigott et al. 2015).”
From The clinical symptoms of Parkinson's disease. (2016) · cites this paper as Pigott et al. 2015
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,310
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,168
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 1×
“These findings are in contrast to those reported for MCI in the general population, in which the majority of patients will not progress to dementia even after 10 years of follow-up.(26) Using total DRS-2 score to control for global cognitive performance at baseline, demographic predictors of progression to cognitive i…”
Research works printed but not linked: 1
- Jurica PJ, Leitten SL, Mattis S. Dementia Rating Scale-2 (DRS-2): Professional Manual. Odessa, FL: Psychological Assessment Resources; 2001.
Cited by
Sorted by citations
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C. G., Chaudhuri, К. R., & Weintraub, D. A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,540
Self-citationThe clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Self-citationIrwin, D. J., Grossman, M., Weintraub, D. A., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Deerlin, V. M. V., López, O. L., Kofler, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 606
Self-citationSchrag, A. E., Siddiqui, U. F., Anastasiou, Z., Weintraub, D. A., & Schott, J. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30328-3 · Cited by 421
Self-citationRisk factors for non-motor symptoms in Parkinson's disease.
Marinus, J., Zhu, K., Marras, C., Aarsland, D., & van Hilten, J. V. (2018) · Lancet Neurology · doi:10.1016/s1474-4422(18)30127-3 · Cited by 302
Natural course of mild cognitive impairment in Parkinson disease
Pedersen, K. F., Larsen, J. P., Tysnes, O., & Alves, G. W. (2017) · Neurology · doi:10.1212/wnl.0000000000003634 · Cited by 270
The relevance of gender in Parkinson’s disease: a review
Picillo, M., Nicoletti, A. S. Q., Fetoni, V., Garavaglia, B., Barone, P., & Pellecchia, M. T. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8384-9 · Cited by 274
Sex differences in movement disorders
Meoni, S., Macerollo, A., & Moro, E. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0294-x · Cited by 207
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
Aamodt, W. W., Waligórska, T., Shen, J., Tropea, T. F., Siderowf, A. D., Weintraub, D. A., Grossman, M., Irwin, D. J., Wolk, D. A., Xie, S. X., et al. (2021) · Movement Disorders · doi:10.1002/mds.28779 · Cited by 179
Self-citationIrwin, D. J., & Hurtig, H. I. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000444 · Cited by 177
Self-citationThe Neuropsychiatry of Parkinson Disease: A Perfect Storm
Weintraub, D. A., & Mamikonyan, E. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.03.002 · Cited by 172
Self-citationCaspell‐Garcia, C., Simuni, T., Tosun, D., Wu, I.-W., Zhang, Y., Nalls, M. A., Singleton, A., Shaw, L. M. J., Kang, J., Trojanowski, J. Q., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175674 · Cited by 155
Self-citationGPNMB confers risk for Parkinson’s disease through interaction with α-synuclein
Diaz-Ortiz, M. E., Seo, Y., Posavi, M., Carceles Cordon, M., Clark, E., Jain, N., Charan, R., Gallagher, M. D., Unger, T. L., Amari, N., et al. (2022) · Science · doi:10.1126/science.abk0637 · Cited by 158
Self-citationDementia in Parkinson's disease
Hanagasi, H. A., Tüfekçıoğlu, Z., & Emre, M. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.012 · Cited by 156
Impacts of exercise interventions on different diseases and organ functions in mice
Guo, S., Huang, Y., Yan, Z., Huang, H., Hong, S., & Liu, T. (2019) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2019.07.004 · Cited by 159
Cognitive decline in Parkinson’s disease: the complex picture
Biundo, R., Weis, L., & Antonini, A. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.18 · Cited by 150
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders
Coughlin, D. G., Xie, S. X., Liang, M., Williams, A., Peterson, C. S., Weintraub, D. A., McMillan, C. T., Wolk, D. A., Akhtar, R. S., Hurtig, H. I., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25392 · Cited by 150
Self-citationSmith, K. M., & Caplan, D. N. (2018) · Brain and Language · doi:10.1016/j.bandl.2018.08.002 · Cited by 144
Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis
Saredakis, D., Collins‐Praino, L. E., Gutteridge, D. S., Stephan, B. C. M., & Keage, H. A. D. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.04.020 · Cited by 153
Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease
Cholerton, B., Johnson, C. O., Fish, B. E., Quinn, J. F., Chung, K. A., Peterson‐Hiller, A. L., Rosenthal, L. S., Dawson, T. M., Albert, M., Hu, S., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.007 · Cited by 137
Roalf, D. R., Rupert, P. E., Mechanic-Hamilton, D. J., Brennan, L., Duda, J. E., Weintraub, D. A., Trojanowski, J. Q., Wolk, D. A., & Moberg, P. J. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8841-8 · Cited by 124
Self-citationA growth-factor-activated lysosomal K+ channel regulates Parkinson’s pathology
Wie, J., Liu, Z., Song, H., Tropea, T. F., Yang, L., Wang, H., Liang, Y., Cang, C., Aranda, K., Lohmann, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03185-z · Cited by 120
Self-citationGonzález-Latapí, P., Bayram, E., Litvan, I., & Marras, C. (2021) · Behavioral Sciences · doi:10.3390/bs11050074 · Cited by 128
Sleep and circadian rhythms in Parkinson’s disease and preclinical models
Hunt, J., Coulson, E. J., Rajnarayanan, R. V., Oster, H., Videnović, A., & Rawashdeh, O. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00504-w · Cited by 118
Differences in the Presentation and Progression of Parkinson's Disease by Sex
Iwaki, H., Blauwendraat, C., Leonard, H. L., Makarious, M. B., Kim, J. J., Liu, G., Maple‐Grødem, J., Corvol, J., Pihlstrøm, L., van Nimwegen, M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28312 · Cited by 103
Self-citationMRI biomarkers of motor and non-motor symptoms in Parkinson's disease
Ryman, S. G., & Poston, K. L. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.10.002 · Cited by 106
Guo, Y., Xu, W., Liu, F., Li, J., Cao, X., Tan, L., Wang, J., & Yu, J. (2019) · Movement Disorders · doi:10.1002/mds.27665 · Cited by 96
Long-Term Dementia Risk in Parkinson Disease
Gallagher, J., Gochanour, C., Caspell‐Garcia, C., Dobkin, R. D., Aarsland, D., Alcalay, R. N., Barrett, M. J., Chahine, L. M., Chen‐Plotkin, A. S., Coffey, C. S., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209699 · Cited by 98
Self-citationWood, K. H., Nenert, R. E., Miften, A. M., Kent, G. W., Sleyster, M., Memon, R. A., Joop, A., Pilkington, J., Memon, A., Wilson, R. N., et al. (2024) · Movement Disorders · doi:10.1002/mds.29908 · Cited by 92
Nicoletti, A. S. Q., Luca, A., Baschi, R., Cicero, C. E., Mostile, G., Davì, M., Pilati, L., Restivo, V., Zappia, M., & Monastero, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00021 · Cited by 88
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease
Elfil, M., Bahbah, E. I., Attia, M. M., Eldokmak, M., & Koo, B. B. (2020) · Movement Disorders · doi:10.1002/mds.28412 · Cited by 88
Dementia in Parkinson's disease: Is male gender a risk factor?
Cereda, E., Cilia, R., Klersy, C., Siri, C., Pozzi, B., Reali, E., Colombo, A., Zecchinelli, A., Mariani, C. B., Tesei, S., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.02.024 · Cited by 83
Kamińska, M., Mery, V., Lafontaine, A., Robinson, A. R., Benedetti, A., Gros, P., & Kimoff, R. J. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7114 · Cited by 79
Neuropsychiatric Issues in Parkinson’s Disease
Cooney, J. W., & Stacy, M. A. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0647-4 · Cited by 75
Hoogland, J., van Wanrooij, L. L., Boel, J. A., Goldman, J. G., Stebbins, G. T., Dalrymple‐Alford, J. C., Marras, C., Adler, C. H., Junqué, C., Pedersen, K. F., et al. (2018) · Movement Disorders · doi:10.1002/mds.110 · Cited by 74
Self-citationReduced cognitive function in patients with Parkinson disease and obstructive sleep apnea
Mery, V., Gros, P., Lafontaine, A., Robinson, A. R., Benedetti, A., Kimoff, R. J., & Kamińska, M. (2017) · Neurology · doi:10.1212/wnl.0000000000003738 · Cited by 75
Brennan, L., Siderowf, A. D., Rubright, J. D., Rick, J. H., Dahodwala, N. A., Duda, J. E., Hurtig, H. I., Stern, M., Xie, S. X., Rennert, L., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.02.020 · Cited by 72
Self-citationParkinson’s Disease and Cognitive Impairment
Yang, Y., Tang, B., & Guo, J. (2016) · Parkinson s Disease · doi:10.1155/2016/6734678 · Cited by 79
Parkinson disease-associated cognitive impairment
(2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00286-x · Cited by 73
Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks
Jellinger, K. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010498 · Cited by 73
Initial cognitive changes in Parkinson's disease
Weintraub, D. A., Tröster, A. I., Marras, C., & Stebbins, G. T. (2018) · Movement Disorders · doi:10.1002/mds.27330 · Cited by 69
Self-citationLiu, T., Zuo, H., Ma, D., Song, D., Zhao, Y., & Cheng, O. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02843-5 · Cited by 59
Vascular Risk Factors and Cognition in Parkinson’s Disease
Pilotto, A., Turrone, R., Liepelt‐Scarfone, I., Bianchi, M., Poli, L., Borroni, B., Alberici, A., Premi, E., Formenti, A., Bigni, B., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150610 · Cited by 57
Mind the gaps: What we don't know about cognitive impairment in essential tremor
Louis, E. D., Joyce, J. L., & Cosentino, S. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.038 · Cited by 58
Purri, R., Brennan, L., Rick, J. H., Xie, S. X., Deck, B. L., Chahine, L. M., Dahodwala, N. A., Chen‐Plotkin, A. S., Duda, J. E., Morley, J. F., et al. (2020) · Movement Disorders · doi:10.1002/mds.28115 · Cited by 62
Self-citationCognitive heterogeneity in Parkinson’s disease: A mechanistic view
Carceles‐Cordon, M., Weintraub, D., & Chen‐Plotkin, A. S. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.021 · Cited by 63
Self-citationEspay, A. J., Guskey, M. T., Norton, J. C., Coate, B., Vizcarra, J. A., Ballard, C. G., Factor, S. A., Friedman, J. H., Lang, A. E., Larsen, N. J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27488 · Cited by 56
Self-citationAlmgren, H., Camacho, M., Hanganu, A., Kibreab, M., Camicioli, R. M., Ismail, Z., Forkert, N. D., & Monchi, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-37644-6 · Cited by 52
Step length predicts executive dysfunction in Parkinson’s disease: a 3-year prospective study
Amboni, M., Iuppariello, L., Iavarone, A., Fasano, A. A., Palladino, R., Rucco, R., Picillo, M., Lista, I., Varriale, P., Vitale, C., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8973-x · Cited by 52
Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Gibson, L. L., Weintraub, D. A., Lemmen, R., Perera, G., Chaudhuri, К. R., Svenningsson, P., & Aarsland, D. (2024) · Movement Disorders · doi:10.1002/mds.29918 · Cited by 55
Self-citationBiomarkers for cognitive dysfunction in Parkinson's disease
Kalia, L. V. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.023 · Cited by 49
Corticostriatal beta oscillation changes associated with cognitive function in Parkinson’s disease
Paulo, D. L., Qian, H., Subramanian, D., Johnson, G. W., Zhao, Z., Hett, K., Kang, H., Kao, C., Roy, N. C., Summers, J. E., et al. (2023) · Brain · doi:10.1093/brain/awad206 · Cited by 49
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
Tropea, T. F., Xie, S. X., Rick, J. H., Chahine, L. M., Dahodwala, N. A., Doshi, J. J., Davatzikos, C. A., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2017) · Movement Disorders · doi:10.1002/mds.27204 · Cited by 51
Self-citationYu, R., & Wu, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.943438 · Cited by 49
Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?
Biundo, R., Weis, L., Fiorenzato, E., & Antonini, A. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx092 · Cited by 49
Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease
Longardner, K., Bayram, E., & Litvan, I. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00897 · Cited by 48
Cholinergic and perfusion brain networks in Parkinson disease dementia
Colloby, S. J., McKeith, I. G., Burn, D. J., Wyper, D. J., O'Brien, J. T., & Taylor, J. (2016) · Neurology · doi:10.1212/wnl.0000000000002839 · Cited by 49
Akhtar, R. S., Xie, S. X., Chen, Y. J., Rick, J. H., Gross, R. G., Nasrallah, I. M., Deerlin, V. M. V., Trojanowski, J. Q., Chen‐Plotkin, A. S., Hurtig, H. I., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177924 · Cited by 49
Self-citationEffects of Antiparkinson Medication on Cognition in Parkinson’s Disease: A Systematic Review
Roy, M., Doiron, M., Talon, J., Dupré, N., & Simard, M. (2018) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.21 · Cited by 46
Parkinson disease and cognitive impairment
Davis, A. A., & Racette, B. A. (2016) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000285 · Cited by 45
Sousa, N. M. F., & Macedo, R. C. (2019) · Dementia & Neuropsychologia · doi:10.1590/1980-57642018dn13-040006 · Cited by 44
Ghanem, A., Berry, D. S., Burkes, A., Grill, N., Hall, T. M., Hart, K. A., Hernandez, N. C., Chapman, S., Sharma, V. D., Huey, E. D., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26927 · Cited by 44
Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment
Altmann, V., Schumacher-Schuh, A. F., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R. M., & Hutz, M. H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.030 · Cited by 43
The efficacy of apomorphine – A non-motor perspective
Rosa‐Grilo, M., Qamar, M. A., Evans, A. H., & Chaudhuri, К. R. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.11.020 · Cited by 43
Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures
Kim, H. M., Nazor, C., Zabetian, C. P., Quinn, J. F., Chung, K. A., Hiller, A., Hu, S., Leverenz, J. B., Montine, T. J., Edwards, K. L., et al. (2019) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2019.08.006 · Cited by 42
Cross-sectional associations between cognition and mobility in Parkinson’s disease
Sousa, N. M. F., Macedo, R. C., & Brucki, S. M. D. (2021) · Dementia & Neuropsychologia · doi:10.1590/1980-57642021dn15-010011 · Cited by 41
The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias
Ciafone, J., Little, B., Thomas, A. J., & Gallagher, P. (2019) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617719001103 · Cited by 41
Parkinson’s Disease: Cognitive Impairment
Mack, J., & Marsh, L. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160043 · Cited by 48
Training working memory updating in Parkinson’s disease: A randomised controlled trial
Fellman, D., Salmi, J., Ritakallio, L., Ellfolk, U., Rinne, J. O., & Laine, M. (2018) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2018.1489860 · Cited by 40
Bezdíček, O., Ballarini, T., Herman Buschke, L., Růžička, F., Roth, J., Albrecht, F., Růžička, E., Mueller, K., Schroeter, M. L., & Jech, R. (2019) · Neuropsychology · doi:10.1037/neu0000503 · Cited by 38
Mashima, K., Ito, D., Kameyama, M., Osada, T., Tabuchi, H., Nihei, Y., Yoshizaki, T., Noguchi, E., Tanikawa, M., Iizuka, T., et al. (2017) · European Neurology · doi:10.1159/000464322 · Cited by 38
Liu, Y., Tong, S., Ding, L., Liu, N., & Gao, D. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5222 · Cited by 34
Picillo, M., Initiative, F. T. P. P. M., Lafontant, D.-E., Bressman, S., Caspell‐Garcia, C., Coffey, C. S., Cho, H. R., Burghardt, E. L., Dahodwala, N. A., Saunders-Pullman, R. J., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212892 · Cited by 34
Self-citationSex differences in alpha-synucleinopathies: a systematic review
Raheel, K., Deegan, G., Giulio, I. D., Cash, D., Ilić, K., Gnoni, V., Chaudhuri, К. R., Drakatos, P., Moran, R., & Rosenzweig, I. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1204104 · Cited by 33
van de Weijer, S. C. F., Hommel, A. L. A. J., Bloem, B. R., Nonnekes, J. H., & de Vries, N. M. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.09.002 · Cited by 33
Sex differences in Parkinson's Disease: An emerging health question
Ferreira, L. P. D. S., da Silva, R. A., da Costa, M. M. M., Roda, V. M. D. P., Vizcaino, S., Janisset, N. R. L. L., Vieira, R. R., Sanches, J. M., Soares, J. M., & Simões, M. D. J. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100121 · Cited by 31
Trends and hotspots in non-motor symptoms of Parkinson’s disease: a 10-year bibliometric analysis
Li, X., Chen, C., Pan, T., Zhou, X., Sun, X., Zhang, Z., Wu, D., & Chen, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1335550 · Cited by 37
Plasma MIA , CRP , and Albumin Predict Cognitive Decline in Parkinson's Disease
Shen, J., Amari, N., Zack, R., Skrinak, R. T., Unger, T. L., Posavi, M., Tropea, T. F., Xie, S. X., Deerlin, V. M. V., Dewey, R. B., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26410 · Cited by 31
Self-citationIhle, A., Oris, M., Fagot, D., Chicherio, C., van der Linden, B. W. A., Sauter, J., & Kliegel, M. (2017) · Applied Neuropsychology Adult · doi:10.1080/23279095.2017.1306525 · Cited by 31
Thach, A., Jones, E., Pappert, E. J., Pike, J., Wright, J., & Gillespie, A. (2021) · BMC Neurology · doi:10.1186/s12883-021-02074-2 · Cited by 30
Gruber, D., Calmbach, L., Kühn, A. A., Krause, P., Kopp, U. A., Schneider, G., & Kupsch, A. R. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01972-7 · Cited by 34
Boccalini, C., Carli, G., Pilotto, A., Padovani, A., & Perani, D. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105668 · Cited by 30
Factors Associated With Responsiveness to Gait and Balance Training in People With Parkinson Disease
Löfgren, N., Conradsson, D. M., Joseph, C., Leavy, B., Hagströmer, M., & Franzén, E. (2018) · Neurology Report · doi:10.1097/npt.0000000000000246 · Cited by 30
Saldert, C., & Bauer, M. (2017) · Brain Sciences · doi:10.3390/brainsci7100123 · Cited by 29
Corneal nerve fiber loss relates to cognitive impairment in patients with Parkinson’s disease
Che, N.-N., Jiang, Q., Ding, G.-X., Chen, S., Zhao, Z., Li, X., Malik, R. A., Ma, J., & Yang, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00225-3 · Cited by 29
Zhang, J., Cao, Y.-L., Li, K., Wang, F., Wang, Y., Wu, J., Pei, S., Chen, J., Mao, C., & Liu, C. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.11.025 · Cited by 27
Neuropsychological Subgroups in Non-Demented Parkinson’s Disease: A Latent Class Analysis
Brennan, L., Devlin, K. M., Xie, S. X., Mechanic-Hamilton, D. J., Tran, B., Hurtig, H. H., Chen‐Plotkin, A. S., Chahine, L. M., Morley, J. F., Duda, J. E., et al. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171081 · Cited by 27
Self-citationNonmotor Symptoms in Parkinson's Disease
Akbar, U., D'Abreu, A., & Friedman, J. (2017) · Seminars in neurology · doi:10.1055/s-0037-1602424 · Cited by 120
Cognitive Training in Parkinson’s Disease: A Review of Studies from 2000 to 2014
Glizer, D., & MacDonald, P. A. (2016) · Parkinson s Disease · doi:10.1155/2016/9291713 · Cited by 30
Önder, H., & Ozyurek, O. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04874-9 · Cited by 26
Costa, A., Peppe, A., Zabberoni, S., Scalici, F., Caltagirone, C., & Carlesimo, G. (2018) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2018.05.016 · Cited by 22
Bezdíček, O., Červenková, M., Moore, T. M., Georgi, H. S., Šulc, Z., Wolk, D. A., Weintraub, D. A., Moberg, P. J., Jech, R., Kopeček, M., et al. (2018) · Assessment · doi:10.1177/1073191118778896 · Cited by 24
Self-citationFrequency of and risk factors for potentially inappropriate medication use in Parkinson’s disease
Abraham, D. S., Nguyen, T. P. P., Hennessy, S., Weintraub, D. A., Gray, S. L., Xie, D., & Willis, A. W. (2020) · Age and Ageing · doi:10.1093/ageing/afaa033 · Cited by 23
Self-citationFagot, D., Chicherio, C., Albinet, C. T., André, N., & Audiffren, M. F. (2017) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2017.1372357 · Cited by 27
Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease
Safarpour, D., & Willis, A. W. (2016) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317516653823 · Cited by 21
Trošt, M., Perovnik, M., & Pirtošek, Z. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01204 · Cited by 20
Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment
Gozalbo, A. S., Rodríguez‐Blázquez, C., Forjaz, M. J., & Martínez‐Martín, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00731 · Cited by 23
Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants
Deck, B. L., Xie, S. X., Choi, G., Rick, J. H., Siderowf, A. D., Rudovsky, S., Chen‐Plotkin, A. S., Duda, J. E., Morley, J. F., Dahodwala, N. A., et al. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12781 · Cited by 20
Self-citation
Metadata
- Authors
- Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., Siderowf, A., Trojanowski, J. Q., & Weintraub, D.
- Affiliations
- Veterans Health Administration (US)
- From the Departments of Neurology (K.P., J.R., H.H., A.C.-P., J.E.D., J.F.M., L.M.C., N.D., R.S.A., D.W.), Pathology and Laboratory Medicine (J.Q.T.), and Psychiatry (D.W.), Perelman School of Medicine at the University of Pennsylvania; the Department of Biostatistics and Epidemiology (S.X.X.), University of Pennsylvania; Philadelphia Veterans Affairs Medical Center (J.E.D., J.F.M., D.W.); and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA.
- ORCID
- Venue
- Neurology
- Published
- 2015-10-13
- Volume
- 85
- Issue
- 15
- Pages
- 1276-1282
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4617168
- OpenAlex
- W1414124913
- Cited by
- 251
- References
- 34
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 26 · 2023: 23 · 2022: 28 · 2021: 27 · 2020: 24 · 2019: 19 · 2018: 24 · 2017: 30 · 2016: 18 · 2015: 1
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- American Brain Foundation
- CHDI Foundation
- Teva Pharmaceutical Industries
- University of Pennsylvania
- ACADIA Pharmaceuticals
- Avanir Pharmaceuticals
- H. Lundbeck A/S
- National Institutes of Health (AG 17586, NS053488)
- Avid Radiopharmaceuticals
- National Institute on Aging (AG 024904, AG 029213, AG-19724, P30AG010124, P01AG017586, AG17586, AG-10124, U01AG029213, K23AG034236, P01AG032953, P01AG019724)
- National Institute of Neurological Disorders and Stroke (NS053488, P50NS053488, K08NS093127, U01NS082134, UO1 NS082134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive impairment, mild cognitive impairment, dementia, cognitive decline, conversion to dementia, predictors of cognitive decline, sex differences, motor score, Unified Parkinson's Disease Rating Scale
- MeSH terms
- Aged, Cognition, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Prospective Studies, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
